Stratification of remaining lifetime risk for unaffected patients with CHEK2 PV (n = 459) on the basis of (A) the Tyrer-Cuzick model alone, (B) a combination of CHEK2 and Tyrer-Cuzick, and (C) the PRS, CHEK2, and Tyrer-Cuzick combined or for patients with ATM PV (n = 216) on the basis of (D) the Tyrer-Cuzick model alone, (E) a combination of ATM and Tyrer-Cuzick, and (F) the PRS, ATM, and Tyrer-Cuzick combined. PRS, polygenic risk score; PV, pathogenic variant.